This article addresses the 8 clinical-stage companies researching the treatment of a wide variety of illnesses using marijuana of which 6 have market capitalizations in excess of $50M and less than $500M and 2 have market capitalizations in excess of $37M.

(For some insight into 12 clinical-stage companies researching the treatment of a variety of mental illnesses based on the use of "magic mushrooms" (psilocybin), "magic" psilocybin truffles, ketamine, DMT, Ibogaine, LSD, MDMA, 5-MeO-DMT, and mescaline you are encouraged to read Psychedelic Stocks: Which Have The Greatest Potential?) 

1. Allied Corp. (ALID): Market Cap. of $86M
   • The company is researching, creating, and producing targeted cannabinoid health solutions to help people suffering from:
     • Post-Traumatic Stress Disorder (PTSD), anxiety, and depression in addition to growing and processing the cannabis plant itself and developing a line of therapeutic CBD-based products.
   • Allied's stock price is DOWN -10.8% since the end of May but is UP 34.7% YTD. 
2. Corbus Pharmaceuticals (CRBP): Market Cap. of $155M
   • The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes such as:
     • Dermatomyositis (in Phase 3) and
     • Systemic Lupus Erythematosus (in Phase 2).
   • Corbus' stock price is DOWN -42.9% since the end of May and is unchanged YTD.
3. Enveric Biosciences (ENVB): Market Cap. of $40M
   • Enveric is endeavoring to enhance the lives of those who are adversely affected by the side effects of cancer treatments such as:
     • radiodermatitis and chemotherapy-induced peripheral neuropathy as well as the treatment of glioblastoma. 
   • Enveric's stock price is DOWN -19.9% since the end of May and DOWN -56.3% YTD.
4. MGC Pharmaceuticals (MGCLF): Market Cap. of $73M
   • MGC has developed a pipeline of phytocannabinoid derived medications for the treatments of:
   • Neurology diseases such as:
     • Refractory Epilepsy, Dementia, Alzheimer’s Disease, and Cerebral Palsy.
   • Oncology related to:
     • anorexia-cachexia and glioblastoma, melanoma, and prostate cancers.
   • MGC's stock price is DOWN -25% since the end of May but is UP +50% YTD.
5. Revive Therapeutics (RVVTF): Market Cap. of $106M
   • The company has been granted two Orphan Drug Designations by the FDA for the use of CBD:
     • in the treatment of: Autoimmune Hepatitis, and
     • in the prevention of Ischemia and Reperfusion Injury resulting from solid organ transplantation, such as liver, kidney, heart, and lungs.
   • Revive's stock price is DOWN -13.2% since the end of May and is DOWN -32.7% YTD.
6. Tetra Bio-Pharma (TBPMF): Market Cap. of $102M
   • The Company is focused on developing cannabinoid-derived medicines for the treatment of:
     • inflammation (Cytokine Release Syndrome),
     • cancer pain (Qixleef and Caumz which are in Phase 2),
     • ophthalmology (Uveitis, and Proliferative Vitreoretinopathy which has an Orphan Drug Designation), and
     • oncology (Cancer Cachexia which is in Phase 2 and Hepatocellular Carcinoma which has an Orphan Drug Designation).
   • Tetra Bio's stock price is DOWN -19.4% since the end of May and is UP +66.7% YTD.
7. Zelira Therapeutics (ZLDAF): Market Cap. of $73M
   • The company is:
     • testing a range of the company’s cannabinoid-based formulations and protocols in pre-clinical research for the treatment of pancreatic cancer, breast cancer, brain cancer, and diabetes-associated cognitive decline, pediatric autism, chronic pain, and chronic insomnia.
   • Zelira's stock price is DOWN -25% since the end of May and is DOWN -50% YTD.
8. Zynerba Pharmaceuticals (ZYNE): Market Cap. of $37M
   • The company hopes to provide new treatment options for patients battling certain rare neuro-psychiatric diseases (those affecting fewer than 200K patients in the U.S.) and near-rare neuropsychiatric conditions (i.e. those affecting fewer than one million patients).
   • Its clinical pipeline consists of research into:
     • Fragile X Syndrome (FXS);
     • 22q Deletion Syndrome (22q);
     • Autism Spectrum Disorder (ASD) and
     • a heterogeneous group of rare and ultra-rare epilepsies known as Developmental & Epileptic Encephalopathies (DEE) and
     • Autoimmune conditions such as Chron's Disease, IBS, and Eczema.
   • Zynerba's stock price is DOWN -21.8% since the end of May but is UP +35.5% YTD.